APRE Stock — Aprea Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.52

Market cap

$7.3M

Cash

$37.9M

Enterprise value

-$30.6M

Balance sheet

Cash	$37.9M
Debt	$0.0M
Net cash	$37.9M
Enterprise value	-$30.6M
Basic shares	14.2M shares
Fully diluted shares	103.1M shares
Fully diluted market cap	$53.6M
Cash per share	$2.67
Quarterly burn	$3.3M
Cash runway	12.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

12.6M

Pre-funded warrants

41.1M

Options

0.8M

RSUs

0.0M

Warrants

48.5M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

103.1M

Cap table as of 2026-06-30.

Price history

Loading APRE daily closes…

Loading price history…

Next catalyst

APR-1051 · Nov 20, 2026 · guided in 13d

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDNov 20, 2026 in 13d	APR-1051 ACESOT-1051 Phase 1 oral presentation at EORTC-NCI-AACR · NCT06260514	Phase 1	Not disclosed	2026-11-20
Jul 13 - Aug 24 in 8 mo	APR-1051	Phase 1	Advanced Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

APR-1051

Phase 1 · Active Modality: oral small-molecule WEE1 kinase inhibitor

Target WEE1

Indications

biomarker-defined cancers (Phase 1)

Status note Phase 1 ACESOT-1051 dose-escalation study ongoing; lead clinical program; no discontinuation disclosed.

ATRN-119

Phase 1 · Active Modality: oral macrocyclic small-molecule ATR inhibitor

Target ATR

Indications

advanced solid tumors (Phase 1)
hematologic malignancies (potential combinations) (Phase 1)

Status note ABOYA-119 Phase 1/2a study closed after RP2D determination; company exploring investigator-initiated combination studies; no discontinuation disclosed.

DYRK1A/B inhibitor

Preclinical · Active Modality: macrocyclic small-molecule DYRK1A/B inhibitor

Target DYRK1A/B

Indications

not disclosed (Preclinical)

Catalysts

— Q4 2026

Status note Early-stage program; IND-enabling studies potentially in Q4 2026 subject to resources.

APR-246

Stage not disclosed · Active Modality: reactivator of mutant p53

Target mutant p53

Indications

not disclosed (Stage not disclosed)

Status note No ongoing clinical trials; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	APR-1051
Lead indication	Advanced Solid Tumor
Lead phase	Phase 1
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06260514	Phase 1	Recruiting	Sponsor	Aprea Therapeutics	—	Advanced Solid Tumor	2026-11-20
NCT07578467	Phase 1/2	Not yet recruiting	Collaborator	Abramson Cancer Center at Penn Medicine	—	HPV Positive Oropharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma; HPV (Human Papillomavirus)-Associated Carcinoma	—
NCT07617363	Phase 1	Not yet recruiting	Collaborator	Washington University School of Medicine	—	Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Aprea Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	270,000	no change	0.03%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

APRE — Aprea Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

APRE — Aprea Therapeutics Inc.